Kuros Bioscience Ltd./ CH0325814116 /
| 2024-09-25 4:22:06 PM | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 22.0000USD | - | 565 Turnover: 11,000 |
-Bid Size: - | -Ask Size: - | 800 mill.USD | - | - |
Fundamentals
| FY 2023 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | -0.38 CHF | -11.63% |
| EPS Diluted: | - CHF | 65.22% |
| Revenues per Share: | 0.92 CHF | 86.57% |
| Book Value per Share: | 1.55 CHF | -17.64% |
| Cash Flow per Share: | -0.24 CHF | 20.33% |
| Dividend per Share: | - CHF | - |
| Total | in mill. | |
| Revenues: | 33.56 CHF | 86.57% |
| Net Income: | -13.73 CHF | -5.98% |
| Operating Cash Flow: | -8.84 CHF | - |
| Cash and Cash Equivalents: | 14.21 CHF | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | - | - |
| P/S Ratio: | 20.17 | 3.80 |
| P/BV ratio: | 11.94 | 2.25 |
| P/CF Ratio: | -76.56 | -14.43 |
| PEG: | 4.19 | - |
| Earnings Yield: | -2.05% | -10.89% |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | 800 mill. USD | 151.69 mill. USD |
| Free Float Market Cap.: | - USD | - USD |
| Market Cap. / Employee: | 10 mill. USD | 1.9 mill. USD |
| Shares Outstanding: | 36.56 mill. | |
Profitability
| Gross Profit Margin: | 71.31% |
| EBIT Margin: | -39.30% |
| Net Profit Margin: | -40.90% |
| Return on Equity: | -24.20% |
| Return on Assets: | -19.21% |
Financial Strength
| Liquidity I / Cash Ratio: | 107.74% |
| Liquidity II / Quick Ratio: | 156.36% |
| Liquidity III / Current Ratio: | 206.22% |
| Debt / Equity Ratio: | 26.01% |
| Dynam. Debt / Equity Ratio: | -166.80% |
Efficiency
| Employees: | 80 |
| Personal Expenses / Employee: | - CHF |
| Revenues / Employee: | 419,550.00 CHF |
| Net Income / Employee: | -171,587.50 CHF |
| Total Assets / Employee: | 893,300.00 CHF |
| * Fiscal Year End: | 2023-12-31 |
| Accounting Standard: | IFRS |
| Currency: | CHF |
